As described in detail throughout this issue, the BcrAbl tyrosine kinase is a well-validated therapeutic target in chronic myeloid leukemia (CML). Present in 95% of patients with CML, Bcr-Abl has been demonstrated to be a leukemogenic oncogene in animal studies and is considered the causative molecular abnormality of CML. Bcr-Abl functions as a constitutively activated tyrosine kinase, impacting numerous signaling pathways. However, all of the transforming activities of Bcr-Abl are dependent on its tyrosine kinase activity (Lugo et al., 1990) . Thus, an inhibitor of the Bcr-Abl kinase would be predicted to be an effective and selective therapeutic agent for CML.
Development of imatinib (STI571)
Compounds that possess inhibitory activity for protein tyrosine kinases were initially isolated from natural sources in the early to mid 1980s. These compounds include the flavinoid, quercetin, the isoflavinoid, genistein, the antibiotic herbimycin A, and erbstatin (Boutin, 1994; Casnellie, 1991; Chang and Geahlen, 1992) . Although these compounds can revert cells transformed by tyrosine kinase oncogenes to a nontransformed phenotype, none of these compounds have demonstrated specificity among tyrosine kinases. In the late 1980s, Yaish et al. (1988) synthesized a series of compounds, known as tyrphostins, that were the first compounds to display specificity among tyrosine kinases. One of the tyrphostins, AG1112, inhibits the Abl protein tyrosine kinase, and induces differentiation and death of a Bcr-Abl-positive, erythroid blast crisis, CML cell line, K562 (Anafi et al., 1993; Kaur et al., 1994) . Similar data for induction of K562 differentiation has been obtained with genistein, herbimycin A, and erbstatin (Honma et al., 1989 (Honma et al., , 1990 Kawada et al., 1993) .
Working independently, scientists at Ciba-Geigy (now Novartis) identified a 2-phenylaminopyrimidine as a weakly potent and non-specific kinase inhibitor. A series of related compounds were then synthesized and using structure-activity relationships, these compounds were optimized against a variety of targets (Buchdunger et al., 2001; Druker and Lydon, 2000) . STI571 (signal transduction inhibitor) was one of many compounds developed in this program and was found to be a potent inhibitor of the platelet-derived growth factor receptor (PDGF-R) and the Abl tyrosine kinases. Further testing revealed that it was relatively selective for the Abl tyrosine kinases, including BcrAbl, c-Abl, v-Abl, and Arg (Abl-related gene) (Buchdunger et al., 2001; Okuda et al., 2001) . Besides the Abl and PDGF-R alpha and beta tyrosine kinases, the only other tyrosine kinase inhibited by STI571 is cKit (Table 1) . STI571 (formerly CGP57148, now Glivec, Gleevec, or imatinib mesylate) emerged as the lead compound for clinical development based on its superior in vitro selectivity against CML cells and its drug-like properties, including pharmacokinetic and formulation properties.
Preclinical studies
Initial studies of imatinib showed that it specifically inhibited the proliferation of Bcr-Abl-expressing cells in vitro, including colony-forming assays from CML patients, and inhibited the growth of Bcr-Abl tumors in vivo (Druker et al., 1996) . These studies have been confirmed by numerous laboratories and demonstrate that imatinib, at concentrations of 1 and 10 mM, kills or inhibits the proliferation of all Bcr-Abl-expressing cell lines tested to date (Beran et al., 1998; Buchdunger et al., 2001; Carroll et al., 1997; Deininger et al., 1997; Gambacorti-Passerini et al., 1997) . In contrast, a variety of immortalized or transformed cell lines that do not express Bcr-Abl are not sensitive to imatinib. In colony forming assays using CML bone marrow or peripheral blood samples, treatment with imatinib decreases the number of colonies formed and may select for the growth of Bcr-Abl-negative progenitor cells (Deininger et al., 1997; Druker et al., 1996; Marley et al., 2000) . Minimal inhibition of the colony forming potential of normal bone marrow has been observed. Similar results, showing selective depletion of Bcr-Abl-positive cells, have been observed in long-term marrow cultures (Kasper et al., 1999) . Thus, imatinib appears to be selectively toxic to cells expressing the constitutively active Bcr-Abl protein tyrosine kinase. Studies in mice also showed that imatinib had in vivo activity against Bcr-Abl-expressing cells. Initial experiments failed to eradicate Bcr-Abl-expressing tumors (Druker et al., 1996) . However, subsequent experiments, using a three times per day administration schedule, allowing continuous exposure to imatinib, achieved eradication of tumors (le Coutre et al., 1999) . This suggested that continuous exposure to imatinib would be important for optimal anti-leukemic effects.
Clinical trials
Phase I studies A standard dose-escalation, Phase I study of imatinib began in June 1998 at three centers in the United States. The study population consisted of CML patients in chronic phase, refractory or resistant to interferon-a-based therapy or intolerant of this drug (Druker et al., 2001b) . At later stages of the study, patients with CML in blast crisis and patients with Phchromosome positive acute lymphoblastic leukemia were also enrolled (Druker et al., 2001a) . Imatinib was well tolerated with minimal side effects. Despite dose escalation from 25 to 1000 mg in 14 cohorts of patients, a maximally tolerated dose could not be defined. Imatinib was administered once daily and pharmacokinetics showed a half-life of 13 -16 h. Significant clinical benefits were observed at daily doses above 300 mg. In chronic phase patients who had failed therapy with interferon, 53/54 (98%) patients treated with 5300 mg per day achieved a complete hematologic response and 96% of these responses lasted beyond 1 year (Druker et al., 2001b) . In myeloid blast crisis patients, 21/38 (55%) patients treated at doses 5300 mg per day responded, with 18% having responses lasting beyond 1 year (Druker et al., 2001a) .
Phase II and III studies of imatinib
The success of the phase I studies prompted phase II studies; single agent imatinib was tested further in interferon refractory and interferon intolerant patients as well as accelerated phase patients and patients with CML in myeloid blast crisis and Philadelphia chromosome positive ALL. These studies accrued over 1000 patients at 30 centers in six countries in 6 -9 months. Results from these studies, with 18 months of followup, have been published and are summarized in Table  2 Ottmann et al., 2002; Sawyers et al., 2002; Talpaz et al., 2002) .
In 532 chronic phase patients who failed interferon therapy, 95% of these patients achieved a complete hematologic response with imatinib at 400 mg per day. Sixty per cent of patients had a major cytogenetic response, defined as a reduction in the percentage of Philadelphia chromosome positive metaphases to less than 35%. Forty-one per cent of patients achieved a complete cytogenetic remission. With a median followup of 18 months, the estimated progression-free survival was 89% . Of 235 accelerated phase patients treated with imatinib, 82% of patients showed some form of hematologic response, Imatinib concentrations causing a 50% reduction in kinase activity (IC 50 ) are given.
a IC 50 was determined in immunocomplex assays. PDGF-R, platelet-derived growth factor receptor; TPK, tyrosineprotein kinase; EGF-R, epidermal growth factor receptor; IGF-IR, insulin-like growth factor receptor I, FGF-R1, fibroblast growth factor receptor 1; VEGF-R, vascular endothelial growth factor receptor; PKA, cAMP-dependent protein kinase; PPK, phosphorylase kinase; PKC, protein kinase C; CK, casein kinase. . Results of the phase II study treating 260 myeloid blast crisis patients with imatinib showed an overall response rate of 52% with sustained hematologic responses, lasting at least 4 weeks, in 31% of patients . Major cytogenetic responses were seen in 16% of patients, with 7% having complete responses. Median survival was 6.9 months. 20% of patients were still alive at 18 months with a suggestion of a plateau on the survival curve. These results compare favorably to historical controls treated with chemotherapy for myeloid blast crisis in which the median survival is approximately 3 months. In patients with Ph positive acute lymphoblastic leukemia, the majority of patients responded to single agent imatinib, 29/48 (60%). However, the duration of response was relatively short, with a median estimated time to disease progression of only 2.2 months . These Phase II studies confirmed the results from the Phase I studies and served as the basis for accelerated FDA approval of imatinib in May 2001.
A phase III randomized study, comparing imatinib at 400 mg per day to interferon plus cytarabine in newly diagnosed chronic phase CML patients, enrolled 1106 patients from June 2000 to January 2001. Five hundred and fifty-three patients were randomized to each treatment. Baseline characteristics were well balanced for all prognostic features. With a median follow-up of 14 months, patients randomized to imatinib had statistically significant better results than patients treated with interferon plus cytarabine in all parameters measured (Table 3) , including rates of complete hematological response, major and complete cytogenetic responses, tolerance of therapy, and freedom from disease progression (Druker, 2002) . Given the significant difference in percentage of patients with disease progression to accelerated phase or blast crisis, 7% with interferon versus 1.5% of patients randomized to imatinib, it seems likely that this will translate into a survival benefit. A remaining question is the durability of the responses to imatinib.
Side effects of imatinib
One of the surprising aspects of the clinical trials was how well tolerated this therapy has been. Less than 1% of newly diagnosed chronic phase patients discontinued therapy due to adverse events (Druker, 2002) . The rare serious adverse events have included skin rashes, fluid retention, elevated liver function tests, and prolonged myelosuppression. The most common side effects have been mild and include nausea, periorbital edema, muscle cramps, and myelosuppression (Druker et al., 2001b) . The incidence of myelosuppression is much greater in CML patients than in solid tumor patients (Demetri et al., 2002) . This suggests that myelosuppression is a therapeutic effect in CML patients where hematopoiesis is predominantly contributed by the BcrAbl positive clone.
Based on data from null animals, side effects might have been predicted to be much greater. Abl null animals are viable, but have a variety of neurological defects, lymphopenia and typically die shortly after birth (Schwartzberg et al., 1991; Tybulewicz et al., 1991) . Animals lacking either the PDGF-R-a or b die in early gestation with a variety of developmental defects, including neural crest abnormalities (a) and renal, cardiovascular, and hematological abnormalities (b) (Soriano, 1994 (Soriano, , 1997 . Inactivating mutations of Kit results in embryonic lethality due to severe anemia (Russell, 1979) . These animals also have deficiencies in melanocytes, germ cells, and mast cells (Dolci et al., 1991) .
The lack of side effects of imatinib might be due to the lack of a critical role for the kinases targeted by imatinib in an adult animal as opposed to their critical role during embryonic development. Alternatively, humans may have redundant gene function compared with mice that minimizes the effect of loss of these kinases. Lastly, it is possible that residual kinase activity may persist during imatinib therapy and this may be sufficient to protect dependent tissues. If this latter explanation is correct, then side effects might become more apparent as more potent kinase inhibitors are generated.
Dose selection
In the Phase I clinical trials of imatinib, a maximally tolerated dose of STI571 was never reached (Druker et al., 2001b) . Endpoints that might be appropriate for a molecularly targeted agent include pharmacokinetic parameters, optimal therapeutic responses, or molecular endpoints. Regarding pharmacokinetic endpoints, it was known from preclinical studies that continuous exposure of cells to imatinib doses of 1 mM or higher resulted in maximal cell killing . In the Phase I clinical trials, a trough level of 1 mM was reached at a dose level of 300 mg, which corresponds to a threshold for significant therapeutic Table 3 Phase III results of imatinib versus interferon plus cytarabine for newly diagnosed chronic phase CML patients (Druker and Group, 2002) .
Imatinib 400 mg (%) Interferon+Ara-C (%) benefits (Peng et al., 2001) . Thus, pharmacokinetic parameters could have been used to predict therapeutic responses. Similarly, an analysis of responses in blood counts over time suggested that doses of 400 -600 mg were on the plateau of a dose-response curve (Peng et al., 2001) . Thus, an analysis of optimal therapeutic responses led to a similar conclusion that doses greater than 300 mg should be chosen for Phase II trials. However, the analysis of optimal therapeutic responses may not always be available from early clinical trials, particularly since disease free survival may be the best parameter to measure. When using molecularly targeted agents, it would seem more reasonable to consider maximal inhibition of the target as the therapeutic endpoint. In the case of CML and a Bcr-Abl inhibitor, the obvious choice would be to assess for maximal inhibition of Bcr-Abl kinase activity. We and others had shown that in BcrAbl-expressing cells, the SH2, SH3 domain adaptor protein, Crkl, is the major tyrosine phosphorylated protein (Nichols et al., 1994; Oda et al., 1994; ten Hoeve et al., 1994) . As with most phosphoproteins, Crkl migrates as a doublet with the slower migrating form corresponding to the phosphorylated protein. In collaboration with C Sawyers, it was confirmed that this mobility shift was dependent on tyrosine phosphorylation (Senechal et al., 1998) . Based on this, we developed an assay for Bcr-Abl kinase inhibition, by examining the relative proportion of Crkl isoforms before and during treatment. These assays showed that a plateau in inhibition is seen above 250 mg (Druker et al., 2001b) . Additional assays, including ELISA-based assays are under development. Obviously, there are advantages in CML in that the tumor cells are easily accessible and that the kinase itself or its substrates can be easily monitored for inhibition. These types of assays will be more problematic for solid tumors but will be necessary to determine the penetration of agent into the tumor. Regardless, data regarding kinase inhibition could be particularly useful in explaining response variability, determining mechanisms of relapse and to individualize patient dosing.
Mechanisms of relapse/resistance to imatinib
The Crkl assay described above has been particularly useful for categorizing relapsed/resistant patients into those with persistent inhibition of the Bcr-Abl kinase versus those with reactivation of the Bcr-Abl kinase (Figure 1) . Patients with persistent inhibition of the Bcr-Abl kinase would be predicted to have additional molecular abnormalities besides Bcr-Abl driving the growth and survival of the malignant clone. In contrast, patients with persistent Bcr-Abl kinase activity or reactivation of the kinase would be postulated to have resistance mechanisms that either prevent imatinib from reaching the target or render the target insensitive to Bcr-Abl. In the former category are mechanisms such as drug efflux or protein binding of imatinib. In the latter category would be mutations of the Bcr-Abl kinase that render Bcr-Abl insensitive to imatinib and amplification of the Bcr-Abl protein.
Our laboratory was particularly interested in the basis of specificity of imatinib for the Abl kinase and exploring the possibility that point mutations in the Abl kinase might mediate resistance to imatinib. These studies were greatly facilitated by J Kuriyan's laboratory solving the crystal structure of the Abl kinase in complex with an imatinib-related compound (Schindler et al., 2000) . Based on this, numerous mutations in the Abl kinase domain were generated, at sites predicted to form critical contacts with imatinib. Many of these contact points, such as Lys 271, are critical for the binding of ATP and not surprisingly, mutation of these residues resulted in a kinase inactive protein. However, mutation of several residues, most notably Thr 315, significantly decreased the sensitivity of the Abl kinase to imatinib (Corbin et al., 2000 . This residue was subsequently the first kinase domain mutation described in patients mediating resistance to imatinib (Gorre et al., 2001) and is now known to be one of the most common Abl kinase domain mutations seen in patients who relapse on therapy with imatinib.
In the largest studies of resistance or relapse, several consistent themes emerge. In patients with primary resistance, that is, patients who do not respond to imatinib therapy, Bcr-Abl-independent mechanisms are most common . In contrast, the majority of patients who relapse on therapy with imatinib reactivate the Bcr-Abl kinase. In these studies, greater than 50% and perhaps as many as 90% of patients with hematologic relapse have Bcr-Abl point mutations in at least 13 different amino acids scattered throughout the Abl kinase domain (Figure 2 ) (Branford et al., 2002; Hochhaus et al., 2002; Hofmann et al., 2001; Roche-Lestienne et al., 2002; Shah et al., 2002; von Bubnoff et al., 2002) . Other patients have amplification of Bcr-Abl at the genomic or transcript level .
It should be noted that the studies described above represent a minority of CML patients. Most of the patients described had advanced phase disease. The majority of patients diagnosed with CML will be in the chronic phase, most will obtain a complete cytogenetic response with imatinib, and very few have relapsed. However, only a minority attain a molecular remission. It is assumed that if these patients relapse, that similar mechanisms will be operative. However, the more pressing question is the mechanism of molecular resistance, that is, why do residual leukemia cells persist. One postulated mechanism is that quiescent stem cells may be insensitive to imatinib (Graham et al., 2002; Holtz et al., 2002) . If this is true, then management of this group of patients may differ substantially from patients with relapses.
Regardless, in relapsed patients, the Bcr-Abl kinase remains a good target. Abl kinase inhibitors with specificity that differs from imatinib have already been synthesized (Dorsey et al., 2000; Mow et al., 2002; Sun et al., 2001) . Whether these compounds will inhibit some or all of the Bcr-Abl mutations that have been described needs to be determined. It is conceivable that several inhibitors, analogous to cocktails of protease inhibitors for HIV, would be necessary and that the appropriate inhibitors would be chosen based on the molecular profile of mutations present in individual patients. Given that Bcr-Abl kinase activity has been reactivated in relapsed patients, it might also be useful to target downstream signaling pathways, such as Raf/ MEK/ERK, PI-3 kinase, AKT, or ras. For example, two groups recently reported in vitro sensitivity of imatinib resistant Bcr-Abl positive cell lines to a farnesyl transferase inhibitor (Hoover et al., 2002; Topaly et al., 2001) . Moreover, Hoover et al. (2002) observed that this compound sensitized cells to imatinib, even imatinib resistant cell lines. Alternatively, strategies to increase Bcr-Abl protein degradation using agents such as geldanamycin, 17-AAG, or arsenic trioxide might be useful (La Rosee et al., 2002; Porosnicu et al., 2001; Topaly et al., 2001) .
Conclusions
Imatinib is a highly effective therapy for CML, whose development was based on a precise understanding of the molecular pathogenesis of this disease. As our knowledge of the pathogenesis of other cancers increases, it is hoped that this paradigm and the lessons learned from the development of imatinib can be applied to other malignancies. (2002) 
